期刊文献+

抑癌基因PTEN和FHIT在口腔鳞癌中的表达及其与cyclin D1的相关性 被引量:14

Expressions of PTEN and FHIT in oral squamous cell carcinoma and their relations with cyclin D1
下载PDF
导出
摘要 目的检测抑癌基因PTEN、FHIT在正常口腔粘膜上皮和口腔鳞癌(OSCC)中的表达情况,并探讨其与cyclinD1的关系。方法采用免疫组化SP法检测62例OSCC中FHIT、PTEN、cyclinD1蛋白表达的情况,以12例正常口腔粘膜作对照。结果在正常口腔粘膜中PTEN均为强阳性表达(12/12),在OSCC中24.2%(15/62)表现为PTEN蛋白表达的缺乏或减少;而FHIT在正常口腔粘膜中也均为强阳性表达(12/12),在OSCC中17.7%(11/62)表现为FHIT蛋白表达缺乏或减少;cyclinD1在正常口腔粘膜中91.7%(11/12)表现为阴性或弱阳性表达,在OSCC中53.2%(33/62)表现为阳性或强阳性表达;PTEN与FHIT均为阳性或强阳性表达时,37.8%(28/74)cyclinD1表现为阴性或弱阳性,其中11例为正常口腔粘膜(占正常组的91.7%)。结论PTEN、FHIT在OSCC的发生过程中起着一定的作用;PTEN/FHIT的表达与cyclinD1有关,提示PTEN、FHIT能够下调cyclinD1的表达。 Objective To study the expressions of PTEN, FHIT and cyclin D1 in normal oral mucosa and oral squamous cell carcinoma (OSCC), and analyze the relationship between PTEN/FHIT and cyclin D1. Methods Immunohistochemical staining with SP methods was used to detect the expression of PTEN, FHIT and cyclin D1 in OSCC tissues in 62 cases and normal oral mucosa in 12 cases. Results The positivity rates of PTEN and FHIT were both 100% (12/12) in the normal oral mucosa, while in 62 cases of OSCC, 24.2% (15/62) and17.7% (11/62) were negative for (or with low expression of) PTEN and FHIT, respectively. In normal oral mucosa, 91.7% (11/12) cases had negative or low cyclin D1 expression, while 53.2% (33/62) of the OSCC cases were positive for cyclin D1 expression. In all the cases, when PTEN and FHIT were strongly expressed, 37.8% (28/74) of the cases had negative or low expression of cyclin D1, including 11 normal cases. Conclusion The tumor suppressor genes PTEN and FHIT play a role in the pathogenesis of OSCC, and PTEN and FHIT can down-regulate the expression of cyclin D1.
出处 《第一军医大学学报》 CAS CSCD 北大核心 2005年第1期79-82,共4页 Journal of First Military Medical University
基金 广东省医学科研基金(A2002316)~~
关键词 抑癌基因 PTEN FHIT CYCLIN D1 口腔癌 免疫组化 tumor suppresser gene PTEN FHIT cyclin D1 oral cancer immunohistochemistry.
  • 相关文献

参考文献9

  • 1周传香,高文信,魏秀峰.口腔鳞癌发展过程中抑癌基因PTEN的蛋白表达及意义[J].口腔医学研究,2003,19(5):365-367. 被引量:6
  • 2Steck PA, Pershouse MA, Jasser SA, et al. Identification of a candidate tumour suppressor gene, MMAC 1, at chromosome 10q23.3 that is mutated in multiple advanced cancers[J]. Nat Genet, 1997, 15(4):356-62.
  • 3Van Heerden W F, Swart T J, Robson B, et al. FHIT RNA and protein expression in oral squamous cell carcinomas [J]. Anticancer Res, 2001, 21 (4A): 2425-8.
  • 4Chen Q, L.P. Samaranayake LP, Zhou H, et al. Homozygous deletion of the PTEN tumor-suppressor gene is not a feature in oral squamous cell carcinoma[J]. Oral Oncol, 2000, 36(1): 95-9.
  • 5van Heerden WF, Swart T J, Robson B, et al. FHIT RNA and protein expression in oral squamous cell carcinomas [J]. Anticancer Res,2001, 21 (4A): 2425-8.
  • 6Ohta M, Inoue H, Cotticelli M G, et al. The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma associated t (3;8) breakpoint, is abnormal in digestive tract cancers [ J ]. Cell, 1996,84(4): 587-97.
  • 7Lee JI, Soria J C, Hassan K. Loss of ghit rxpression is a predictor of poor outcome in tongue cancer [ J ]. Cancer Research, 2001, 61: 837-41.
  • 8Furnari FB, Huang HJ, Cavenee WK. The phosphoinositol phosphatase activity of PTEN mediates a serum-sensitive G1 growth arrest in glioma cells[J]. Cancer Res, 1998, 58(22): 5002-8.
  • 9Barne S, Larry D, Garriso N, et al. Fhit, a putative tumor suppressor in humans, is a dinucleoside 5′, 5"-P1, P3-triphosphate hydrolase [J ].Biochemistry, 1996, 35(36): 11529-35.

二级参考文献10

  • 1Li J,Yen C,Liaw D,et al. PTEN,a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science, 1997,275 (5308) : 943 - 947.
  • 2Wang SI,Puc J,Li J,et al. Somatic mutations of PTEN in glioblastoma multiforme. Cancer Res, 1997,57 (19) : 4 183 - 4 186.
  • 3Levine RL, Cangile CB, Blazes MS, et al. PTEN mutations and microssatellite instability in complex atypical hyperplasia, a precursorlesion to uterine endometrioid carcinoma. Ca ncer Res,1998,58(15): 3252-3258.
  • 4Fei G, Ebert MP, Mawrin C, et al. Reduced PTEN expression in gastric cancer and in the gastric mucosa of gastric cancer relafives. Eur J Gastroenterol Hepatol,2002,14( 3 ) : 297 - 303.
  • 5Sato K,Tamura G,Tsuchiga T,et al. Analysis of genetic and epigenetic alterations of the PTEN gene in gastric cancer. Virchows Arch,2002,440(2): 160- 165.
  • 6Hong TM,Yang PC,Peck K,et al. Profiling the downstream genes of tumor suppressor PTEN in lung cancer cells by complementary DNA microarray. Am J Respir Cell Mol Biol, 2000,23 ( 3 ) : 355- 363.
  • 7Tetsuro S, Lin H, and Chen XS. Differential expression of MMAC/PTEN in glioblastom a multiforme: Relationship to localization and prognosis. Cancer Res, 1999,59 ( 15 ) : 1 820 - 1 824.
  • 8Lee JI,Soria JC,Hassan KA,et al. Loss of PTEN expression as a prognostic marker for tongue cancer. Arch Otolaryngol Head Neck Surg,2001,127(12) : 1 441 - 1 445.
  • 9Maehama T, Dixon JE. PTEN:a tumor suppressor that functions as a phospholipid phosphatase. Trends Cell Bio1,1999,9(4): 125- 128.
  • 10Chen Q, Samaranayake LP, Zhou H, et al. Homozygous deletion of the PTEN tumor - suppressor gene is not a feature in oral squamous eel carcinoma. Oral Oncol,2000,36 ( 1 ) : 95 - 99.

共引文献5

同被引文献125

引证文献14

二级引证文献39

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部